Quoin Pharmaceuticals Ltd. (QNRX) filings document a State of Israel registrant whose Nasdaq-listed American Depositary Shares each represent 35 ordinary shares. Recent 8-K reports record quarterly and annual financial results, Regulation FD disclosures and material events tied to the company's rare-disease drug-development programs.
The filing record includes disclosures about QRX003 regulatory designations for Netherton Syndrome, QRX009 topical rapamycin delivery technologies, capital-structure matters and board compensation arrangements. These reports also identify the ADS and ordinary-share structure and exchange listing for QNRX securities.
Ikarian Capital, LLC and Neil Shahrestani filed an amended Schedule 13G reporting their beneficial ownership of 211,538 American Depositary Shares (ADS) of Quoin Pharmaceuticals, Ltd., equal to 12.6% of the ADS class based on 1,683,627 ADS outstanding as of January 31, 2026.
The ADS represent ordinary shares of Quoin and are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts over which Ikarian Capital has investment discretion. The filers state the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Quoin.
Quoin Pharmaceuticals (QNRX) reported a new stock option grant to its Chief Financial Officer, Sally Bridget Lawlor. On February 4, 2026, she received an option to purchase 85,250 American Depositary Shares (ADS) at an exercise price of $7.37 per ADS.
The option covers ADSs, each representing thirty-five ordinary shares of Quoin Pharmaceuticals. The award vests over four years, with 20% vesting on each of February 4, 2027, 2028 and 2029, and the remaining 40% vesting on February 4, 2030. The option expires on February 4, 2036 and is held directly by the CFO.
Quoin Pharmaceuticals director Joseph Patrick Cooper reported receiving a new stock option grant. On February 4, 2026, he was awarded options to acquire 8,141 American Depositary Shares at an exercise price of $7.37 per ADS. Each ADS represents thirty-five ordinary shares of Quoin Pharmaceuticals.
The options vest over four years, with 20% becoming exercisable on each of February 4, 2027, 2028, and 2029, and the remaining 40% vesting on February 4, 2030. After this grant, Cooper beneficially owns 8,141 derivative securities directly.
Quoin Pharmaceuticals director granted stock options
Quoin Pharmaceuticals, Ltd. reported that director Anthony James Culverwell received a grant of share options on February 4, 2026. The award covers 21,709 American Depositary Shares (ADSs), each with an exercise price of $7.37 per ADS and no purchase price for the grant itself.
Each ADS represents thirty-five ordinary shares of the company. The option vests over four years, with 20% vesting on each of February 4, 2027, February 4, 2028 and February 4, 2029, and the remaining 40% vesting on February 4, 2030. After this transaction, Culverwell directly holds options over 21,709 ADSs.
Quoin Pharmaceuticals (QNRX) reported an equity award to its CEO and director, Michael Myers. On February 4, 2026, he received a share option covering 318,750 American Depositary Shares (ADSs) at an exercise price of $7.37 per ADS, with no purchase price paid for the grant itself.
The option becomes exercisable in four annual installments: 20% of the ADSs vest on each of February 4, 2027, 2028 and 2029, and 40% vest on February 4, 2030. The option expires on February 4, 2036 and is held directly.
Quoin Pharmaceuticals reported an equity award to its Chief Operating Officer and director Denise P. Carter. On February 4, 2026, she received a share option covering 318,750 American Depositary Shares (ADSs) with an exercise price of $7.37 per ADS, expiring on February 4, 2036.
Each ADS represents thirty-five ordinary shares of Quoin Pharmaceuticals. The option vests in four annual installments, with 20% vesting on each of February 4, 2027, 2028 and 2029, and the remaining 40% vesting on February 4, 2030. Following this grant, she beneficially owns 318,750 derivative securities directly.
Quoin Pharmaceuticals director Dennis Langer received a grant of stock options linked to American Depositary Shares (ADSs). On February 4, 2026, he was awarded options to acquire 21,709 ADSs at an exercise price of $7.37 per ADS. Each ADS represents thirty-five ordinary shares of Quoin Pharmaceuticals. The options vest over four years, with 20% vesting on each of February 4, 2027, 2028, and 2029, and the remaining 40% vesting on February 4, 2030. Following this grant, Langer beneficially owns 21,709 derivative securities directly.
Quoin Pharmaceuticals director Michael T. Sember received a new stock option grant. On February 4, 2026, he was awarded a Share Option (Right to Buy) covering 8,141 American Depositary Shares (ADSs) of Quoin Pharmaceuticals, Ltd. at an exercise price of $7.37 per ADS.
Each ADS represents thirty-five ordinary shares of the company. The option vests over four annual installments, with 20% vesting on each of February 4, 2027, 2028 and 2029, and the remaining 40% vesting on February 4, 2030. Following this grant, Sember holds 8,141 derivative securities directly.
Quoin Pharmaceuticals reported that director Natalie Leong received a grant of share options for 12,211 American Depositary Shares (ADSs) on February 4, 2026. The options have an exercise price of $7.37 per ADS and expire on February 4, 2036. Each ADS represents 35 ordinary shares of the company.
The option vests over four years, with 20% vesting on each of February 4, 2027, 2028, and 2029, and the remaining 40% vesting on February 4, 2030. Following this grant, Leong holds 12,211 derivative securities directly.
Quoin Pharmaceuticals, Ltd. received an amended Schedule 13G showing that Stonepine Capital Management, Stonepine Capital, Stonepine GP and Jon M. Plexico together beneficially own 3,271,100 Ordinary Shares, representing 10.6% of the class as of the reported basis.
The stake is held through American Depositary Shares and warrants, including 93,460 ADSs, pre-funded warrants to acquire 81,212 ADSs and ordinary warrants to acquire 484,848 ADSs. The warrants are subject to a 9.9% beneficial ownership cap and are not currently exercisable. The filers state the securities are not held to change or influence control of Quoin.